Prevention and treatment of high-risk acute myeloid leukemia recurrence after allogeneic hematopoietic stem cell transplantation
10.3969/j.issn.1674-7445.2023.03.007
- VernacularTitle:高危急性髓系白血病异基因造血干细胞移植后复发的防治
- Author:
Jiaqi WANG
1
;
Xinge SHENG
;
Zhihao MA
;
Quanyi LU
Author Information
1. Graduate School of Xiamen University Medical College, Xiamen 361102, China
- Publication Type:Research Article
- Keywords:
Acute myeloid leukemia;
High-risk;
Allogeneic hematopoietic stem cell transplantation;
Minimal residual disease;
Recurrence;
Demethylation drug;
Graft-versus-host disease;
Graft-versus-leukemia
- From:
Organ Transplantation
2023;14(3):364-
- CountryChina
- Language:Chinese
-
Abstract:
Acute myeloid leukemia (AML) is a group of highly-heterogeneous clonal diseases. Chemotherapy and hematopoietic stem cell transplantation are considered as effective treatment for AML. For high-risk AML patients, allogeneic hematopoietic stem cell transplantation is an effective therapeutic option. However, some AML patients may still face the problem of disease recurrence after hematopoietic stem cell transplantation. A majority of recurrent patients cannot be effectively treated by chemotherapy or secondary transplantation, which is the main cause of death after allogeneic hematopoietic stem cell transplantation. Therefore, it is of significance to strengthen follow-up of AML patients after allogeneic hematopoietic stem cell transplantation and implement appropriate measures to prevent postoperative recurrence. In this article, the monitoring, drug prevention and cell therapy of recurrence after allogeneic hematopoietic stem cell transplantation in high-risk AML patients were reviewed, aiming to provide reference for improving clinical prognosis of high-risk AML patients undergoing allogeneic hematopoietic stem cell transplantation.
